$PPHM Recent Headlines Apollo slammed on education

New Post Public Reply Private Reply Replies (0) Message Board

Oct 8, 2014 at 1:14 PM

$PPHM Recent Headlines

Apollo slammed on education department review 6:09 p.m. July 14, 2014 - Tom Bemis
Peregrine plunges on test data 4:17 p.m. June 27, 2013 - Russ Britt
Small-cap makes a splash with FDA nod for cancer drug 3:16 p.m. May 20, 2013 - Russ Britt
Peregrine drug shows promise in pancreatic cancer 1:17 p.m. Feb. 13, 2013 - MarketWatch.com
In focus: Bullish, but overbought 8:06 p.m. Jan. 9, 2013 - Lawrence G. McMillan
Hedge funds are bullish on these stocks 11:57 a.m. Dec. 5, 2012 - Insider Monkey
Peregrine, FDA agree on brain-cancer drug study 11:56 a.m. Dec. 5, 2012 - MarketWatch.com
Drug trial contractors improve efficiency 10:24 a.m. Nov. 16, 2012 - MarketWatch.com
Monday’s biggest gaining and declining stocks 6:42 p.m. Sept. 25, 2012 - Greg Morcroft
Tuesday’s biggest gaining and declining stocks 5:09 p.m. Sept. 25, 2012 - Greg Morcroft
Peregrine Pharma down 86% after test data review 8:27 a.m. Sept. 24, 2012 - Steve Gelsi
Peregrine Pharma down 86% in premarket 8:18 a.m. Sept. 24, 2012 - Steve Gelsi
Peregrine reviewing Bavituximab results 7:42 a.m. Sept. 24, 2012 - Greg Morcroft
Some previous Bavituximab data not valid

eregrine 7:42 a.m. Sept. 24, 2012 - Greg Morcroft
Monday’s biggest gaining and declining stocks 2:42 p.m. Sept. 10, 2012 - MarketWatch
Regions Financial, Williams-Sonoma hit 52-week highs; Intel, Cisco active 11:11 a.m. Sept. 10, 2012 - blogs.marketwatch.com
Stocks to watch Monday: AIG, Michael Kors, Sears 6:41 a.m. Sept. 10, 2012 - MarketWatch
Peregrine rallies on bavituximab lung-cancer data 1:29 p.m. Sept. 7, 2012 - MarketWatch.com
Monday’s biggest gaining & declining stocks 2:53 p.m. Aug. 27, 2012 - MarketWatch
Peregrine Pharma slides 12% after negative report 2:21 p.m. Aug. 27, 2012 - Val Brickates Kennedy

Peregrine Pharmaceuticals' Q1 Loss Wider than Expected - Analyst Blog 9:00 a.m. Sept. 10, 2014 - Zacks.com
Peregrine Pharmaceuticals' (PPHM) CEO Steven King on Q1 2015 Results - Earnings Call Transcript 7:53 p.m. Sept. 9, 2014 - Seeking Alpha
10-Q: PEREGRINE PHARMACEUTICALS INC 4:29 p.m. Sept. 9, 2014 - Edgar Online - (EDG = 10Q, 10K)
Peregrine Pharmaceuticals (PPHM) Q1 2015 Results - Earnings Call Webcast 4:25 p.m. Sept. 9, 2014 - Seeking Alpha
Tekmira Pharmaceuticals Corp. Is More Than Just A Short-Term Trade 3:12 p.m. Aug. 27, 2014 - Seeking Alpha
Cel-Sci Is A Leader In The I-O Class Of Cancer Therapies 10:43 a.m. Aug. 12, 2014 - Seeking Alpha
Peregrine Pharmaceuticals' Q4 Loss Narrower than Expected - Analyst Blog 11:00 a.m. July 15, 2014 - Zacks.com
Peregrine Pharmaceuticals' (PPHM) CEO Steven King on Q4 2014 Results - Earnings Call Transcript 10:21 p.m. July 14, 2014 - Seeking Alpha
10-K: PEREGRINE PHARMACEUTICALS INC 5:00 p.m. July 14, 2014 - Edgar Online - (EDG = 10Q, 10K)
More on Peregrine fiscal Q4 and fiscal year results 4:26 p.m. July 14, 2014 - Seeking Alpha
Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events 9:30 a.m. July 14, 2014 - TheStreet.com
First Week Of January 2015 Options Trading For Peregrine Pharmaceuticals (PPHM) 11:09 a.m. May 20, 2014 - TheStreet.com
Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack 6:00 a.m. May 9, 2014 - TheStreet.com
Peregrine wins law suit 9:24 a.m. May 5, 2014 - Seeking Alpha
Medivation Signs Deal with OncoFusion Therapeutics - Analyst Blog 6:24 p.m. April 24, 2014 - Zacks.com
Interesting PPHM Call Options For June 21st 11:02 a.m. April 23, 2014 - TheStreet.com
Peregrine's Bavituximab has high success rate in animal testing 9:47 a.m. April 7, 2014 - Seeking Alpha
Peregrine Pharmaceuticals (PPHM) Shares March Higher, Can It Continue? - Tale of the Tape 8:39 a.m. March 18, 2014 - Zacks.com
Cel-Sci's Multikine - Potential 21st Century Superdrug 5:41 p.m. March 13, 2014 - Seeking Alpha
Peregrine antibodies boost anti-tumor activity in animal studies 9:47 a.m. March 11, 2014 - Seeking Alpha

Data to Be Presented at CRI Immunotherapy Conference Show PS-Targeting Antibodies Enhance the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Decreasing Levels of Myeloid Derived Suppressor Cells (MDSC) in the Tumor Microenvironment 8:03 a.m. Oct. 6, 2014 - Marketwire
Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2015 Financial Results and Recent Developments 4:01 p.m. Sept. 9, 2014 - Marketwire
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock 4:00 p.m. Sept. 8, 2014 - Marketwire
Peregrine Pharmaceuticals to Report First Quarter Fiscal Year 2015 Financial Results After Market Close on September 9, 2014 4:01 p.m. Sept. 2, 2014 - Marketwire
Preclinical Data Presented at Annual Immunotherapies and Vaccine Summit Show That the Combination of Peregrine Pharmaceuticals' PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce Breast Cancer Progression 8:03 a.m. Aug. 11, 2014 - Marketwire
Small companies lead the I-O class of Cancer Therapies 8:03 a.m. Aug. 8, 2014 - ACCESSWIRE
Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma 9:00 a.m. Aug. 1, 2014 - PR Newswire - PRF
Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal Year 2014 Financial Results and Recent Developments 4:01 p.m. July 14, 2014 - Marketwire
Peregrine Pharmaceuticals to Report Fourth Quarter and Year-End Fiscal 2014 Financial Results After Market on July 14, 2014 4:00 p.m. July 7, 2014 - Marketwire
Technical Scrutiny on Biotech Stocks -- Research on Insmed, Peregrine Pharma, CytRx, and Celldex Therapeutics 6:40 a.m. June 30, 2014 - PR Newswire - PRF
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock 4:00 p.m. June 10, 2014 - Marketwire
Pre-Market Review on Biotechnology Equities -- Research on BioMarin Pharma, Keryx Biopharma, Amgen, and Peregrine Pharma 8:30 a.m. May 30, 2014 - PR Newswire - PRF
Biotech Stocks Scanner -- Research on PDL BioPharma, Cytokinetics, Vical, and Peregrine Pharma 12:41 p.m. May 6, 2014 - PR Newswire - PRF
Peregrine Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab and Ipilimumab (Yervoy(R)) in Advanced Melanoma 7:31 a.m. April 23, 2014 - Marketwire
Healthcare Companies Report Results, Patents, and Stock Movements - Analyst Notes on Puma Biotechnology, Alnylam, INSYS Therapeutics, Peregrine Pharmaceuticals, and VIVUS 12:28 p.m. April 10, 2014 - PR Newswire - PRF
Data Presented at AACR Support Potential of Peregrine's PS-Targeting Immunotherapy Bavituximab to Enhance Anti-Tumor and Immune-Stimulating Effects of Anti-CTLA-4 and Anti-PD-1 Treatments in Models of Melanoma and Colon Cancer 11:01 a.m. April 9, 2014 - Marketwire
Morning Review on Top Gainers -- Research on Peregrine Pharma, Agios Pharma, Idenix Pharma, and Lexicon Pharma 1:15 p.m. April 8, 2014 - PR Newswire - PRF
Data Presented at AACR Support Potential of Combining Peregrine's PS-Targeting Immunotherapy Agent Bavituximab With Irradiation in Lung Cancer 8:04 a.m. April 7, 2014 - Marketwire
Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting 4:01 p.m. April 1, 2014 - Marketwire
Presentation at Annual Society of Surgical Oncology Meeting Updates Progress in Investigator-Sponsored Phase i/ii Trial of Peregrine's Bavituximab in Combination With Sorafenib in Liver Cancer 8:02 a.m. March 14, 2014 - Marketwire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ADT Shareholders Face Legal Scrutiny in M&A Deal

ADT Shareholders on High Alert Listen up, folks. Anyone holding shares in ADT Inc. (NYSE: ADT) needs to sharpen their pencils and start crunching numbers. This isn't the time to sit back and coast. A M&A Class Action investigation is brewing, and it's centered on ADT's sale to Thrive Holdings. The $10.00 per share buyout offer might look neat and tidy, but there's more to...

Main Street Merger Faces Scrutiny: What It Means for Shareholders

Under the Radar, but Not for Long Ah, mergers—those grand gestures in corporate America that promise growth, synergy, and shareholder value. But not every deal is a head-turner; some fly under the radar until someone grabs the magnifying glass. And that's exactly what's happening with Main Street Financial Services Corp.'s (OTC: MSWV) proposed merger with First...

Haunted Attraction Insights from the Queen of Haunts

Admit it—everyone's got that one fear that sends shivers down their spine. Whether it's the slithering scales of a snake or the manic laughter of a clown, those phobias are what make haunted attractions such a hit for thrillseekers across the country. Amber Arnett-Bequeaith, the so-called Queen of Haunts, knows a thing or two about turning those fears into unforgettable...

DKS Lawsuit Deadline: Investors Must Act by Nov 3, 2026

Clock's Ticking for DICK'S Investors If you've got money tied up in DICK'S Sporting Goods—bought between September 8, 2025, and August 24, 2026—listen up. There's a class action lawsuit aiming to recover some of what might've slipped through your fingers. Come November 3, 2026, the door slams shut on your chance to get involved. What's the Beef? Apparently, DICK'S had...

Neuberger Fund Ups Distribution Amid Market Challenges

Neuberger Boosts Distribution: What's Driving This? I ain't about to sugarcoat it: the Neuberger Next Generation Connectivity Fund (NYSE: NBXG) decided to jack up its monthly distribution rate to $0.132 per share. This announcement, hitting wallets on November 30, 2026, has a record and ex-date of November 16. Now, that's a good ol' reliable payout for folks holding NBXG...

ModelBest & OpenBMB Unveil Open-Source OCR Models

A New Frontier in Document Parsing Just when you thought document parsing couldn't get any more advanced, ModelBest and OpenBMB come along with a game-changing release: the MiniCPM-OCR series. This duo of dynamite models, MiniCPM-OCR 1.0 and Jev, is all about taking the efficiency and performance expectations for open-source OCR models up a couple of notches. If you're an...

Fluence Energy Faces Class Action: Investors Beware

Storm Clouds Over Fluence Energy I'll tell you, I ain't surprised when companies face the music for dressing up their books. Fluence Energy, Inc. (NASDAQ: FLNC)—those wallopers are now caught in a legal maelstrom with a securities fraud class action lawsuit hanging over their heads. It's hard to feel sorry for 'em when the writing's on the wall. Allegations and...

BCD Travel Faces Class Action Probe After Data Breach

Class Action Stirred by BCD Travel Data Breach Here's the scoop, folks: Edelson Lechtzin LLP, a heavyweight in the world of class action law firms, is sniffing around BCD Travel Services B.V. over a juicy data breach that left about 700,000 traveler records flapping in the wind. Grab your coffee—this one's got all the trimmings of a modern-day digital fiasco. The Breach...

Rural AI Skills Gap Uncovered: Challenges and Solutions

Rural Workers Face Distinct AI Challenges Ah, life in the countryside might sound serene, but when it comes to keeping up with AI, rural folks aren't sipping lemonade and waiting on a windfall. The newly unveiled paper from the University of Phoenix College of Doctoral Studies shines a floodlight on some hefty challenges facing rural communities—particularly around...

Lawsuit Hits San Ramon Medical: Wages, Breaks in Dispute

Legal Storm Unleashes on San Ramon Regional In the world of legal entanglements, San Ramon Regional Medical Center found itself on the receiving end of the latest workforce fuss. Allegations flying from a class action lawsuit claim the center's brass didn't hold up their end of the California Labor Code, particularly in providing legit meal breaks and rest periods. Now,...